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Background. Androgen deprivation therapy (AD) may increase late toxicity when used concurrently with three-dimensional
conformal radiotherapy (3DCRT).
Purpose. To report late genitourinary (GU), gastrointestinal (GI) and cardiovascular (CV) events in prostate cancer (PCa) patients
treated with high-dose radiotherapy (HDRT) and AD. To analyze whether the duration of AD correlates with a higher risk of
toxicity.
Methods. Between 2005 and 2010, 361 patients with intermediate and high-risk PCa, were randomized to receive 4 months short-
term AD (STAD: 180) or 28 months long-term AD (LTAD: 181), combined with HDRT (78Gy median prostate dose). GU and GI
toxicity were scored according to the RTOG/EORTC criteria and CV events according to the Common Terminology Criteria for
Adverse Events (CTC) version 3.0.
Results. Median follow-up was 42 months (range 6–80). Late GI and GU toxicity≥grade 2 were reported in 5.3% and 16.2% respec-
tively. No signiﬁcant differences between both randomization arms (STAD versus LTAD) were seen for late GI and GU toxicities,
except for urethral stricture (p=0.019). The 4-year cumulative risk of late grade≥2 rectal bleeding was 9.0% for LTAD arm versus
7.2% for STAD arm (p=0.79) and late grade≥2 hematuria was 2.0% versus 3.6%, respectively (p=0.18). The median time to devel-
opment of hematuria grade≥2 was 57.1 months in LTAD arm and 33.2 months in STAD and the median time to bleeding grade≥2
was 13.4 and 19.1 months, respectively. There were 16 CV events in the LTAD and 7 in the STAD treatment arm, none of them
fatal (p=0.10).
Conclusion. Preliminary results show that the combination of AD and HDRT is safe and associated with a low risk of adverse
effects. Late toxicity was independent of AD duration except for urethral stricture. Further follow-up will be needed to validate
these ﬁndings.
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